Inhibition of the TIGIT pathway sustainably enhances the cytotoxic effects of NK cells against lung cancer cells, thereby offering a crucial theoretical basis for advancing clinical immunotherapeutic strategies [211]. This evidence concerns the gene TIGIT and lung carcinoma.